Condition (MeSH)
Ameloblastoma
ClinicalTrials.gov lists 7 trials for Ameloblastoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
7 of the 7 trials are tagged with Ameloblastoma itself; the rest are tagged with a narrower condition beneath it.
When did Ameloblastoma trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2017 | 1 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 7 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ameloblastoma trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Not applicable | 2 |
| Observational | 1 |
How many Ameloblastoma trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Completed | 3 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Ameloblastoma? (21)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach. | Journal of the National Cancer Institute | 2024 | Yes |
| Frequency of Odontogenic Tumors: A Single Center Study of 1089 Cases in Japan and Literature Review. | Head and neck pathology | 2022 | Yes |
| Effectiveness of marsupialisation and decompression on the reduction of cystic jaw lesions: a systematic review. | The British journal of oral & maxillofacial surgery | 2021 | Yes |
| Effect of technetium-99 conjugated with methylene diphosphonate (<sup>99</sup> Tc-MDP) on OPG/RANKL/RANK system in vitro. | Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology | 2019 | Yes |
| Ameloblastoma: current etiopathological concepts and management. | Oral diseases | 2018 | Yes |
Showing 5 of 21 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Ameloblastoma | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Ameloblastoma | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Ameloblastoma | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Ameloblastoma | 314419 | Exact | Orphadata Science knowledge files, Product 1 |
| Ameloblastoma | 314419 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.